ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus
Markus van der Giet,1 Josep M Cruzado,2 Johan W de Fijter,3 Hallvard Holdaas,4 Zailong Wang,5 Antonio Speziale,6 Guido Junge61Department of Nephrology, Campus Benjamin Franklin, Charite'-Universitätsmedizin, Berlin, Germany; 2Department of Nephrology, University Hospital of Bellvitg...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-03-01
|
| Series: | Open Access Journal of Clinical Trials |
| Online Access: | http://www.dovepress.com/elevate-an-innovative-study-design-to-assess-the-efficacy-safety-and-e-a16196 |
| _version_ | 1811251980669026304 |
|---|---|
| author | van der Giet M Cruzado JM de Fijter JW Holdaas H Wang Z Speziale A Junge G |
| author_facet | van der Giet M Cruzado JM de Fijter JW Holdaas H Wang Z Speziale A Junge G |
| author_sort | van der Giet M |
| collection | DOAJ |
| description | Markus van der Giet,1 Josep M Cruzado,2 Johan W de Fijter,3 Hallvard Holdaas,4 Zailong Wang,5 Antonio Speziale,6 Guido Junge61Department of Nephrology, Campus Benjamin Franklin, Charite'-Universitätsmedizin, Berlin, Germany; 2Department of Nephrology, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; 3Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; 4Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; 5Biometrics and Statistical Science, Novartis Pharmaceuticals, East Hanover, NJ, USA; 6Research and Development, Novartis Pharma AG, Basel, SwitzerlandAbstract: Progressive decline in allograft function and cardiovascular mortality after kidney transplantation remain major clinical challenges that can potentially be addressed by the mammalian target of rapamycin (mTOR) inhibitors, everolimus and sirolimus. mTOR inhibitors maintain immunosuppressive efficacy after minimization of calcineurin inhibitor (CNI) therapy and can achieve significant long-term improvements in renal function. Recently, data have accumulated that suggest mTOR inhibitors may offer cardioprotective effects. In animal models, inhibition of mTOR leads to regression of cardiac hypertrophy, and the limited data consistently point to a remodeling benefit following heart transplantation. Experimentally, mTOR inhibitors restrict atherogenesis, confirmed clinically by intravascular ultrasound data demonstrating lower rates of transplant vasculopathy in heart transplant recipients on everolimus. Lastly, mTOR inhibitors appear to ameliorate arterial stiffness, a known risk factor for post-transplant cardiovascular events, but data remain sparse. The ELEVATE study will examine the renal effect of early conversion from CNI therapy to everolimus after kidney transplantation. Key secondary endpoints include the change in left ventricular mass index, the first time this endpoint has been included in a prospective study of an mTOR inhibitor. The occurrence of cardiovascular events will be rigorously documented and pulse wave velocity is being measured in a subpopulation of patients. Results from this innovative trial are awaited with interest.Keywords: cardiovascular, calcineurin inhibitors, ELEVATE, everolimus, kidney transplantation, mammalian target of rapamycin |
| first_indexed | 2024-04-12T16:27:10Z |
| format | Article |
| id | doaj.art-2b8a1685bcc547c999fe5ad96db89b0d |
| institution | Directory Open Access Journal |
| issn | 1179-1519 |
| language | English |
| last_indexed | 2024-04-12T16:27:10Z |
| publishDate | 2014-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Open Access Journal of Clinical Trials |
| spelling | doaj.art-2b8a1685bcc547c999fe5ad96db89b0d2022-12-22T03:25:18ZengDove Medical PressOpen Access Journal of Clinical Trials1179-15192014-03-012014default172716196ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimusvan der Giet MCruzado JMde Fijter JWHoldaas HWang ZSpeziale AJunge GMarkus van der Giet,1 Josep M Cruzado,2 Johan W de Fijter,3 Hallvard Holdaas,4 Zailong Wang,5 Antonio Speziale,6 Guido Junge61Department of Nephrology, Campus Benjamin Franklin, Charite'-Universitätsmedizin, Berlin, Germany; 2Department of Nephrology, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; 3Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; 4Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; 5Biometrics and Statistical Science, Novartis Pharmaceuticals, East Hanover, NJ, USA; 6Research and Development, Novartis Pharma AG, Basel, SwitzerlandAbstract: Progressive decline in allograft function and cardiovascular mortality after kidney transplantation remain major clinical challenges that can potentially be addressed by the mammalian target of rapamycin (mTOR) inhibitors, everolimus and sirolimus. mTOR inhibitors maintain immunosuppressive efficacy after minimization of calcineurin inhibitor (CNI) therapy and can achieve significant long-term improvements in renal function. Recently, data have accumulated that suggest mTOR inhibitors may offer cardioprotective effects. In animal models, inhibition of mTOR leads to regression of cardiac hypertrophy, and the limited data consistently point to a remodeling benefit following heart transplantation. Experimentally, mTOR inhibitors restrict atherogenesis, confirmed clinically by intravascular ultrasound data demonstrating lower rates of transplant vasculopathy in heart transplant recipients on everolimus. Lastly, mTOR inhibitors appear to ameliorate arterial stiffness, a known risk factor for post-transplant cardiovascular events, but data remain sparse. The ELEVATE study will examine the renal effect of early conversion from CNI therapy to everolimus after kidney transplantation. Key secondary endpoints include the change in left ventricular mass index, the first time this endpoint has been included in a prospective study of an mTOR inhibitor. The occurrence of cardiovascular events will be rigorously documented and pulse wave velocity is being measured in a subpopulation of patients. Results from this innovative trial are awaited with interest.Keywords: cardiovascular, calcineurin inhibitors, ELEVATE, everolimus, kidney transplantation, mammalian target of rapamycinhttp://www.dovepress.com/elevate-an-innovative-study-design-to-assess-the-efficacy-safety-and-e-a16196 |
| spellingShingle | van der Giet M Cruzado JM de Fijter JW Holdaas H Wang Z Speziale A Junge G ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus Open Access Journal of Clinical Trials |
| title | ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| title_full | ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| title_fullStr | ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| title_full_unstemmed | ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| title_short | ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| title_sort | elevate an innovative study design to assess the efficacy safety and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus |
| url | http://www.dovepress.com/elevate-an-innovative-study-design-to-assess-the-efficacy-safety-and-e-a16196 |
| work_keys_str_mv | AT vandergietm elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT cruzadojm elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT defijterjw elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT holdaash elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT wangz elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT spezialea elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus AT jungeg elevateaninnovativestudydesigntoassesstheefficacysafetyandevolutionofcardiovascularparametersindenovokidneytransplantrecipientsafterearlyconversionfromacalcineurininhibitortoeverolimus |